ZEN LOSS ALERT: ROSEN LAW FIRM Reminds Zendesk, Inc. Investors of Important December 23rd Deadline in Securities Class Action – ZEN

NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zendesk, Inc. (NYSE: ZEN) between February 6,

Read more

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell responses and favorable safety profile

Read more

Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

STK-001 showed distribution throughout the brain after a single intrathecal injection; Target engagement and increased Nav1.1 protein expression were observed throughout the cortex Safety

Read more